Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes are crucial to prevent lymphoproliferative disease (LPD) in allogeneic stem cell transplant (SCT) recipients. We studied the recovery of EBV-specific CD8+ T cells after partially T-cell-depleted SCT in relation to the occurrence of EBV reactivation and EBV-LPD. We enumerated EBV-specific CD8+ T cells in 61 patients using 12 class I HLA tetramers presenting peptides derived from 7 EBV proteins. EBV DNA levels were assessed by real-time polymerase chain reaction. Forty-five patients reactivated their EBV, reaching high-level reactivation (i.e., >1,000 geq/ml) in 25. Nine of these 25 patients progressed to EBV-LPD. CD8+ T cells specific for lytic or latent EBV epitopes repopulated the peripheral blood at largely similar rates. In most patients, EBVspecific CD8+ T cells had returned to levels observed in healthy EBV carriers within 6 months post SCT. The incidence of EBV reactivations clearly decreased during that period. Patients with delayed EBV-specific CD8+ T-cell recovery were at increased risk for EBV reactivation as compared to those with rapid EBVspecific CD8+ T-cell recovery during the first 6 months after SCT. Failure to detect EBV-specific CD8+ T cells in patients with highlevel reactivation was associated with the subsequent development of EBV-LPD. Consequently, the positive predictive value of approximately 40%, based on high-level EBV reactivation only, increased to 100% when EBV-specific CD8+ Tcells were included. Thus, delayed recovery of EBV-specific CD8+ T cells in patients with high-level EBV reactivation identifies a subgroup at high risk for EBV-LPD, which is in line with the paradigm that EBV-specific T cells protect against progressive EBV reactivation and EBV-LPD.
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Age dependent differentiation status of virus-specific CTLImmunological implications of age as risk factor in stem cell transplantation F.E. Chen, A.I. Dodi, P. Travers, A.J. Madrigal (London, UK) Recent evidence suggests that increasing donor age is associated with poorer allogeneic stem cell transplantation (SCT) outcome (C. Kollman et al, Blood 2001 , 98:2043 . The causes for this are unclear but age-related impairment of immune competence may be contributory. Given that thymus function declines with age, and therefore the production of new T cells is decreased in older individuals, it is clear that from time of the transplant for a variable period, that can be prolonged in older patients, effective immune protection of the patient relies on transplanted mature T cells of donor origin . To analyse the effect of age on the responsiveness of donor peripheral T cells, we characterised the differentiation status of in vitro expanded CTL from donors of different ages. CD 8 T cells isolated from peripheral blood were stimulated with dendritic cells pulsed with immunogenic peptides of EBV, CMV and Influenza. Virus-specific CTL were identified with epitope-specific HLA-A2 and B8 tetramers and differentiation status with antibodies to CCR7 and CD45RA or CD27 and CD28 combinations; the loss of CD28 is associated with late differentiation stage. Donor blood cells from four age groups were used: 20-30, 30-40, 40-50, and 50-60yrs. CD27 and CD28 expression were found to decrease with increasing age. The mean proportion of Ag-specific CTL staining for CD27 in each age group were as follows: 20-30 yrs: 76.5%, 30-40yrs: 57.8%, 40-50yrs: 48%, 50-60yrs: 33%. For CD28 the mean results were: 20-30yrs: 90%, 30-40yrs: 84%, 40-50yrs: 54%. Expression of CCR7 and CD45RA was uninformative for all age differences. Chronic and latent infections (CMV and latent EBV) had a much smaller mean proportion of CD27+ cells (for CMV 48%, EBV EBNA3 76%, EBV-LMP2 61%) compared to acute infections (lytic EBV epitopes GLC 92.6% and RAK 94%; Flu 99.6%). Increased age and latent infections were found to be associated with greater number of cells in the late differentiation stage. This suggests virus-specific T cells become more differentiated after cumulative expansions in response to multiple exposures to viruses. This is in keeping with the concept of 'clonal exhaustion' where antigen-specific T cells have a finite capacity to expand to repeated exposures, and eventually become senescent. This may explain the increased susceptibility of elderly to viral infections and possibly contribute to the poorer outcome of SCT patients with older donors.
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Adenovirus infections in pediatric stem cell transplantation recipients: feasibility of adoptive cellular immunotherapy A. Lankester, B. Heemskerk, T. Vossen, T. Beersma, E. Claas, A.C. Kroes, J. Vossen, M. Schilham, M. van Tol (Leiden, NL) Adenovirus (Ad) infection is an increasing complication in pediatric recipients of allogeneic stem cell transplantation (SCT) and a major cause of morbidity in recipients of unrelated or mismatched donor grafts. From January 1, 2001, all pediatric recipients (n=41) of an allogeneic SCT were prospectively studied for the incidence of Ad infection. Weekly obtained samples of feces, throat swabs and urine were tested for Ad by culture. Plasma was tested weekly for the presence of Ad DNA by RQ-PCR. The incidence of infection as documented by at least one positive culture was high in both HLA-identical and non-HLA-identical SCT (45% versus 57%). However, Ad DNA was only detected in plasma of recipients of a non-HLA-identical graft. Two out of the 11 PCR positive patients died from Ad infection as the major cause of death, 2 and 10 weeks after the first positive plasma PCR result, respectively. In these 2 patients, lymphocyte reconstitution post SCT was absent. In the 9 patients surviving the disseminated infection, recovery of lymphocytes to numbers above 200 per microliter was correlated with a decrease of viral DNA load from ~10e6 copies/ml to undetectable levels. These results suggest that immunological reconstitution is instrumental in controlling Ad infections. Therefore, the feasibility of adoptive cellular immunotherapy for the treatment of SCT recipients at first signs of Ad dissemination was explored. Ad-specific T cells could be stimulated in 80% of healthy donors. T cells, stimulated with methylene blue inactivated Ad to meet GMP conditions, recognized cellular targets infected with infectious virus. Using flowcytometry and intracellular staining for IFNg mainly CD4+ Ad-specific T cells were identified. Ad-specific T cell clones raised against Ad5 (subgroup C) showed various reactivity patterns, including recognition of Ad strains belonging to subgroup A and B. These results indicate t hat cross-reactive Ad-specific T cells can be generated from donor PBMC using inactivated Ad, and that there is a time window to administer these T cells in patients at an early sign of disseminated infection.
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Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, and conditioning regimen
During follow-up after allogeneic SCT, patients frequently lose immunity to infectious agents such as measles. The aim of this study was to analyse the influence of different factors on the possibility to lose immunity to measles. 377 patients who had a disease free survival of at least one year after allogeneic SCT were included in the analysis. Antibody levels were determined by ELISA. Antibody levels at each time point were classified as certain immunity, uncertain immunity, or as seronegative. Measles vaccination was given to children and young adults without chronic GVHD or ongoing immunosuppression at two years after SCT. The median age was 27 years (1-63). 259 patients had undergone matched sibling SCT and 118 either mismatched family donor or unrelated donor SCT. 312 patients received bone marrow and 65 peripheral blood stem cells. 364 patients had undergone myeloablative and 13 non-myeloablative conditioning. Overall 129/377 (34%) patients had become seronegative and 74/377 (20%) had uncertain immunity. Younger patient age, measles vaccination rather than measles disease before transplantation, use of bone marrow, and chronic GVHD were significant risk factors for becoming seronegative in univariate analysis. In multivariate analysis either patient age or pretransplant measles vaccination, and chronic GVHD were significant risk factors for seronegativity while the use of bone marrow grafts was not. Only 1/13 patients who had undergone non-myeloablative SCT became seronegative. Since nonmyeloablative conditioning was only used in adults, a separate analysis including only adults was performed. In this model, bone marrow grafts and chronic GVHD were significant risk factors for seronegativity while myeloablative conditioning was not. Donor type had no influence on the risk of becoming seronegative in any of the models. C hronic GVHD and weaker antigen stimulation such as after vaccination are associated with loss of immunity to measles. Stem cell source is important to retain immunity in adults.
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Reduced risk for extensive chronic GVHD in patients given PCR-based preemptive anti-CMV therapy K. Larsson, J. Aschan, K. Niemelä, M. Remberger, O. Ringdén, J. Winiarski, P. Ljungman (Stockholm, S) The role of CMV infection as a risk factor for chronic GVHD has been controversial. CMV-induced CD13-specific autoimmunity has been proposed as a possible cause of chronic GVHD. In a previous study from Huddinge University Hospital it was shown that a close correlation existed between the finding of CD13-specific autoantibodies and later development of chronic GVHD and that patients with CMV disease had a higher risk for developing extensive chronic GVHD. PCR-based monitoring for CMV DNA allows earlier initiation of preemptive therapy and thereby a lower production of CMV antigens. The aim of this study was therefore to analyse the impact of PCR-based preemptive therapy on the risk for chronic GVHD. We included a homogenous group of patients in the analysis -269 consecutive patients, who received stem cells from HLA-identical sibling donors and who were given cyclosporine and methotrexate as GVHD prophylaxis. The median age at transplantation was 34 years (range 1-58). The overall mortality was 47.2%, of which 3.7% was related to CMV. 33 patients did not survive for at least one hundred days and could not be evaluated concerning cGVHD; hence they were excluded from the risk factor analysis. 102 patients were monitored for CMV infection with rapid virus isolation and 134 patients by pp65 antigenemia (n=5) or a qualitative PCR for CMV DNA (n=129). 50% of the patients developed cGVHD, of whom 20% developed extensive cGVHD. Risk factors for development of extensive cGVHD were determined by multivariate logistic regression. Low donor age and PCR-based CMV preemptive therapy significantly decreased the risk for developing extensive cGVHD (p=0.02 and 0.004) Recipient age, donor and recipient sex and aGVHD grade II-IV did not have any significant effect on the development on extensive cGVHD. We conclude that the risk for extensive chronic GVHD in this homogenous group of patients was reduced by the use of PCR based preemptive therapy. Therefore the hypothesis that CMVinduced CD13-specific autoimmunity plays a role in the development of chronic GVHD was supported by this study.
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Increased incidence of Epstein-Barr virus-related disease following pediatric stem cell transplant with reduced intensity conditioning M. Gandhi, J. Cohen, P. Naik, K. Rao, D. Cubitt, P. Amrolia, H.B. Gaspar, G. Davies, P. Veys (London, UK) EBV-related lymphoproliferative disease (LPD) is uncommon following non-T cell depleted stem cell transplantation (SCT) using conventional intensity conditioning (CIC). However, recent reports have highlighted the occurrence of EBV LPD following reduced intensity conditioning (RIC) SCT in adults. The aim of this study was to assess the incidence of EBV viraemia, and associated LPD in a consecutive cohort of paediatric patients undergoing RIC SCT. 128 patients [malignant disease (47), genetic disorder (81) and 7/68 (10%) children experienced EBV viraemia following RIC and CIC respectively, at a mean time of 90 days and with a mean number of DNA copies of 1 million (range 1,000 to 10 million). Following CIC 5/38 (13%) and 2/14 (14%) children receiving in vivo Campath and ATG respectively developed EBV viraemia; all were asymptomatic and none developed LPD. Following RIC 9/35 (26%) and 13/29 (45%) patients developed EBV viraemia after in vivo Campath and ATG respectively; 17/23 patients with EBV had concurrent reactivation of CMV (n=8) or adenovirus (n=4) or both (n=5). 8/23 patients had asymptomatic EBV viraemia, 8 patients had associated fever/rash, and 7 patients developed LPD, 2 of whom died of EBV LPD. In 2/7 patients with LPD, EBV appeared to originate from the recipient B-cell pool. Specific therapy included Ganciclovir (n=18), Rituximab (n=13), DLI (n=1) and EBV-specific CTLs (n=2). Ganciclovir had little impact on viral load but early use of Rituximab appeared to be efficacious. In conclusion, EBV-related viraemia and LPD appear to be more common following RIC SCT in children particularly with the use of ATG. The high incidence of concurrent reactivation of other viruses suggests that this may be due to profound immunosuppression following RIC SCT. The relative failure to eradicate recipient B cells with RIC versus CIC may be partly responsible. Although the use of Campath to remove recipient/donor B as well as T cells reduces the occurrence of EBV viraemia following RIC, the incidence remains high.
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Symptomatic RSV infection treated with aerosolized ribavirin in patients undergoing hematopoietic transplantation C. Vallejo, R. Martino, R. Cámara, M. Jurado, M. Cámara, N. Rabella, A. Miñano, E. Pérez, A. Martínez (Murcia, Barcelona, Madrid, Granada, E) Background: RSV infection is an important cause of respiratory disease in HT recipients. In these patients, RSV upper and lower respiratory tract infection (URTI and LRTI), if untreated, progress to pneumonia in at least 25% cases. Once pneumonia develops, its mortality is over 80% with no treatment, and still very high (60%) with the best antiviral and support management. Early diagnosis and prompt treatment of RVS infection to prevent progression to pneumonia is a standard practice in many BMT centres. But, because of the lack of randomised prospective studies, the gold standard for the management of RSV disease in HT recipients is not well established yet. We describe the characteristics and outcome of a group of patients with symptomatic RSV infection treated with aerosolised Ribavirin. Patients and methods: Fifteen patients undergoing HT (12 allogeneic -1 unrelated-and 3 autologous) were diagnosed with symptomatic RSV infection. It occurred in winter (January through March) in 13 cases, in October in one case, and in May in another one. The patients' ages ranged from 14 to 69 years old (median: 48). Conditioning was BuCy (6), Fludarabine-based (4), Cy-TBI (2), BuMel (1), Mel-140 (1), and BEAM (1). Stem cell source was PB in 12 cases and BM in 3. The day of transplant at the onset of the infection ranged from +2 to +840 (median: +105). Seven patients were lymphopenic, while just one was neutropenic. Most of the allogeneic HT patients (10 out of 12) had GVHD and/or immunosuppressive therapy. Nine patients had URTI, 3 LRTI and 3 pneumonia. In addition to other microbiological tests, studies for RSV were performed in HT patients with acute respiratory symptoms by means of indirect immunofluorescence. In most cases, specimens consisted of profound nasopharingeal washes; bronchial aspirates and BAL were also studied when available. All patients with documented RSV infection received aerosolised Ribavirin at 2 gr. over 2 hours three times a day for seven days; one patient treated for advanced pneumonia died without having finished the treatment. Intravenous immunoglobulin was added in 9 cases. Results: In all patients (12) treated for URTI or LRTI (pre-emptive treatment) the illness resolved with no progression to pneumonia. Two of the three patients who received the treatment for pneumonia succumbed to the infection. There were no major adverse effects due to the therapy. Conclusions: In HT recipients, pre-emptive therapy for RSV disease with aerosolised Ribavirin was a safe and efficient approach to prevent progression to pneumonia and death. Like in previous reports, in our series RSV pneumonia had a high mortality rate in spite of the therapy, particularly if Ribavirin was started when pneumonia was advanced.
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Profile of infectious complications following allogeneic HLAidentical sibling transplantation with anti-T-lymphocyte globulin-based reduced-intensity preparative regimen M. Mohty, W. Jacot, C. Faucher, L. Collet, C. Zandotti, K. Bilger, N. Vey, A.M. Stoppa, D. Coso, P. Viens, C. Chabannon, J.A. Gastaut, D. Maraninchi, D. Blaise (Marseille, F) Reduced-intensity preparative regimen (RIC) has been shown to allow engraftment with minimal early TRM. However, in the context of RIC, the profile of infectious complications remains unknown. In this report, we analyzed the features of 75 consecutive high risk patients who received a RIC including fludarabine, busulfan and anti-T lymphocyte globulin (ATG, ImtixSangstat). Median age of recipients was 50 y. . 31 patients (41%) were treated for myeloid malignancies, whereas 29 patients (39%) had lymphoid malignancies. 15 (20%) patients had refractory metastatic non-hematological malignancies. 38 patients received a BM graft, whereas 37 received PBSC. 8 donor/recipient pairs (11%) were CMV seronegative. As part of the protocol, the ATG dose was progressively decreased from 10 mg/kg to 2.5 mg/Kg with the aim of modulating GVHD and toxicity. 40 patients received the higher ATG dose (10 or 7.5 mg/kg), while 35 patients received the lower ATG dose of 2.5 mg/Kg. ANC >500/µL and platelet engraftment were reached respectively at a median of 15 days (range, 9-23) and 14 days (range, 0-99). 34 patients experienced a CMV blood infection episode at a median of 35 days (range, 7-104). The cumulative incidence of CMV reactivation reached 45% (95% CI, 34%-56%). None of these patients developed a CMV disease, and 44% of CMV infections occurred while patients had not experienced any sign of acute GVHD. When looking for factors predictive of the likelihood of CMV reactivation, the latter was significantly associated with the ATG dose infused during conditioning (high ATG dose, 60% vs. low ATG dose, 28%; P= .006). 19 patients (25%; 95% CI, 15%-35%) experienced a bacterial infection at a median of 67 days (range, 7-172) post-allo-SCT, of whom only one infection during the neutropenic phase. Gram negative bacteria were the main source of bacterial infections (68%). The cumulative incidence of fungal infections (6 invasive aspergillosis and 2 others) reached 9% (95% CI, 3%-16%) occurring at a median of 80 days (range, 7-166) post-allo-SCT. Overall, with a median FU of 532 days (range, 149-1326), only 5 patients (7%; 95% CI, 2%-15%) died of infectious complications of whom 3 from invasive aspergillosis. Collectively, these results suggest that a low ATG dose-based RIC allo-SCT is associated with a low incidence of infections without an increased TRM, thus providing a platform for the refinement of low intensity approaches designed to enhance the GVT effect with an acceptable risk of infections.
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Autologous hematopoietic stem cell transplantation of Crohn's disease R. Burt, R. Craig, A. Traynor, Y. Oyama (Chicago, USA) Eight patients with severe Crohn's disease, defined by a Crohn's Disease Activity Index (CDAI) greater than 250 despite antitumor necrosis factor alpha (remicaide) have been enrolled (2 awaiting treatment), six have been mobilized, and five have been treated by intense immune suppression and autologous hematopoietic stem cell transplantation (HSCT). Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and G-CSF (10 ug/kg/day), enriched ex vivo by CD34+ selection (isolex), and reinfused after immune conditioning with cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (ATG) (90 mg/kg). HSCT were complicated by 24-48 hours of culture negative fever. Patients diarrhea and abdominal pain resolved prior to hospital discharge. Perianal fistulae gradually closed over several months, and abdominal masses and colonic strictures have resolved. All patients have remained in clinical remission (CDAI < 100) since HSCT (range 3-18 months) off all immune suppressive or modulating drugs. Albumin, hemoglobin, and weight have improved or normalized. Small bowel radiographs have gradually normalized over 12 months. Colonoscopy has revealed marked improvement but occasional asymptomatic ulcerations remain. We report the worlds first HSCTs for an indication of Crohn's disease. We conclude that further investigations of HSCT for Crohn's disease are warranted
